GES-13, a β-Lactamase Variant Possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa | Zendy

Stathis D. Kotsakis | Zendy; Costas C. Papagiannitsis | Zendy; Εva Tzelepi | Zendy; N.J. Legakis | Zendy; Vivì Miriagou | Zendy; L. S. Tzouvelekis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

GES-13, a β-Lactamase Variant Possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa

Author(s) -

Stathis D. Kotsakis,

Costas C. Papagiannitsis,

Εva Tzelepi,

N.J. Legakis,

Vivì Miriagou,

L. S. Tzouvelekis

Publication year - 2010

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01561-09

Subject(s) - aztreonam , integron , pseudomonas aeruginosa , imipenem , cephalosporin , microbiology and biotechnology , cefsulodin , pseudomonadaceae , biology , pseudomonadales , thienamycin , chemistry , genetics , bacteria , antibiotics , ceftazidime , antibiotic resistance

GES-13 β-lactamase, a novel GES variant possessing Lys-104 and Asn-170, was identified inPseudomonas aeruginosa. bla GES-13 was the single gene cassette of a class 1 integron probably located in the chromosome. GES-13 efficiently hydrolyzed broad-spectrum cephalosporins and aztreonam. Imipenem was a potent inhibitor of GES-13 but was not hydrolyzed at measurable rates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research